Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

33.00

Mkt cap

1.9B

Volume

328K

High

33.18

P/E Ratio

15.56

52-wk high

41.61

Low

32.42

Div yield

N/A

52-wk low

27.14

Harmony Biosciences (NASDAQ:HRMY) has presented new secondary endpoint data from its Phase 2 study evaluating pitolisant for the treatment of excessive daytime sleepiness in Prader-Willi syndrome. The data showed improvements in behavioral disturbances. The company also announced plans to initiate its Phase 3 registrational TEMPO study in Q4 2023. Pitolisant is marketed as WAKIX® in the U.S. and is FDA approved to treat EDS or cataplexy in adult patients with narcolepsy.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 12:07 pm

Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $54.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 2:39 pm

Harmony Biosciences has received a notice from Novugen Pharma and Lupin, seeking approval to manufacture and sell a generic version of Wakix in the U.S. This information was disclosed in a SEC 8K filing.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 12:12 pm

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has extended the expiration of its tender offer to acquire all outstanding shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to October 10, 2023. The tender offer was previously set to expire on September 26, 2023. As of September 26, 2023, approximately 32.1% of Zynerba's outstanding common stock has been tendered.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 12:04 pm

Goldman Sachs analyst Corinne Jenkins has maintained a 'Sell' rating on Harmony Biosciences (NASDAQ:HRMY) and lowered the price target from $40 to $31.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:30 pm

Harmony Biosciences (NASDAQ:HRMY) has received 8 bullish, 2 somewhat bullish, and 1 bearish rating from analysts in the last quarter. The average price target is $59.0, indicating an upside from the current price of $33.13. This average has increased by 9.26% from the previous average price target of $54.00.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 9:00 pm

Goldman Sachs has downgraded Harmony Biosciences from Neutral to Sell and reduced its price target from $40 to $31. This has resulted in a decrease in the trading price of Harmony Biosciences shares.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 2:04 pm

Goldman Sachs analyst Corinne Jenkins has downgraded Harmony Biosciences (NASDAQ:HRMY) from Neutral to Sell and lowered the price target from $40 to $31.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:09 pm

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:09 pm

The FDA has responded to Scorpion Capital's citizen petition, stating that it has been unable to reach a decision due to the complex issues raised requiring extensive review and analysis by agency officials.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 7:53 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.